MXPA04007506A - Carnitina en tratamiento de depresion geriartrica. - Google Patents
Carnitina en tratamiento de depresion geriartrica.Info
- Publication number
- MXPA04007506A MXPA04007506A MXPA04007506A MXPA04007506A MXPA04007506A MX PA04007506 A MXPA04007506 A MX PA04007506A MX PA04007506 A MXPA04007506 A MX PA04007506A MX PA04007506 A MXPA04007506 A MX PA04007506A MX PA04007506 A MXPA04007506 A MX PA04007506A
- Authority
- MX
- Mexico
- Prior art keywords
- carnitine
- acid
- medicament
- levels
- pme
- Prior art date
Links
- 229960004203 carnitine Drugs 0.000 title abstract description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 title 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 20
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- IOFGIBIENKWNQA-UHFFFAOYSA-N methane;2,2,2-trifluoroacetic acid Chemical compound C.OC(=O)C(F)(F)F IOFGIBIENKWNQA-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000935 antidepressant agent Substances 0.000 abstract description 6
- 229940005513 antidepressants Drugs 0.000 abstract description 3
- -1 alkanoyl L-carnitine Chemical compound 0.000 abstract description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 37
- 230000000994 depressogenic effect Effects 0.000 description 27
- 229950007002 phosphocreatine Drugs 0.000 description 18
- 230000002360 prefrontal effect Effects 0.000 description 15
- 150000004713 phosphodiesters Chemical class 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 210000004227 basal ganglia Anatomy 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 208000024714 major depressive disease Diseases 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000003001 depressive effect Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- INAPMGSXUVUWAF-UOTPTPDRSA-N 1D-myo-inositol 1-phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-UOTPTPDRSA-N 0.000 description 2
- 241001136782 Alca Species 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- VTKMMWSAJLCWSM-UHFFFAOYSA-H dialuminum;5-(carbamoylamino)-2-oxo-1,5-dihydroimidazol-4-olate;chloride;tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)N=C1[O-] VTKMMWSAJLCWSM-UHFFFAOYSA-H 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 208000011736 mal de Debarquement Diseases 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000000782 polymeric membrane extraction Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- JATPLOXBFFRHDN-DDWIOCJRSA-N [(2r)-2-acetyloxy-3-carboxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].CC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C JATPLOXBFFRHDN-DDWIOCJRSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000002124 flame ionisation detection Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- JZNWSCPGTDBMEW-YFKPBYRVSA-N sn-glycero-3-phosphoethanolamine Chemical compound NCCO[P@@](O)(=O)OC[C@@H](O)CO JZNWSCPGTDBMEW-YFKPBYRVSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35432302P | 2002-02-07 | 2002-02-07 | |
| PCT/IT2003/000023 WO2003066041A1 (en) | 2002-02-07 | 2003-01-23 | Carnitine in the treatment of geriatric depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007506A true MXPA04007506A (es) | 2004-11-10 |
Family
ID=27734357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007506A MXPA04007506A (es) | 2002-02-07 | 2003-01-23 | Carnitina en tratamiento de depresion geriartrica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040009926A1 (enExample) |
| EP (1) | EP1471904A1 (enExample) |
| JP (1) | JP2005523269A (enExample) |
| KR (1) | KR20040083471A (enExample) |
| AR (1) | AR038350A1 (enExample) |
| AU (1) | AU2003219511A1 (enExample) |
| CA (1) | CA2469925A1 (enExample) |
| MX (1) | MXPA04007506A (enExample) |
| PL (1) | PL374082A1 (enExample) |
| WO (1) | WO2003066041A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272812A1 (en) * | 2002-02-07 | 2005-12-08 | Pettegrew Jay W | Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans |
| US7407778B2 (en) | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
| US7700074B2 (en) | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| EP1641806B1 (en) | 2003-05-29 | 2009-07-29 | Jay W. Pettegrew | Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders |
| PT2582368T (pt) | 2010-06-16 | 2018-06-04 | Alfasigma Spa | Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal |
| CA2964971C (en) | 2014-10-28 | 2023-04-11 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
| US11918336B2 (en) * | 2019-02-19 | 2024-03-05 | King Abdullah University Of Science And Technology | Reduced feature generation for signal classification based on position weight matrix |
| EP4149437A1 (en) | 2020-05-15 | 2023-03-22 | Alfasigma S.p.A. | Composition comprising methylfolate |
| CA3238205A1 (en) * | 2021-11-12 | 2023-05-19 | Rajaram Samant | A synergistic composition for activating intracellular secondary messenger(camp) pathway |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
| US5879884A (en) * | 1994-12-29 | 1999-03-09 | Peroutka; Stephen J. | Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394 |
| JP3425276B2 (ja) * | 1995-08-11 | 2003-07-14 | 株式会社日立製作所 | 情報通知システム |
| JPH10143640A (ja) * | 1996-11-15 | 1998-05-29 | Nippon Lsi Card Kk | 携帯コンピュータ及びそれを用いた情報管理システム並びにそれを用いた立体地図の作成方法 |
| US5889055A (en) * | 1997-04-04 | 1999-03-30 | Howard; James R. | L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism |
-
2003
- 2003-01-23 JP JP2003565465A patent/JP2005523269A/ja active Pending
- 2003-01-23 WO PCT/IT2003/000023 patent/WO2003066041A1/en not_active Ceased
- 2003-01-23 AU AU2003219511A patent/AU2003219511A1/en not_active Abandoned
- 2003-01-23 MX MXPA04007506A patent/MXPA04007506A/es unknown
- 2003-01-23 PL PL03374082A patent/PL374082A1/xx unknown
- 2003-01-23 CA CA002469925A patent/CA2469925A1/en not_active Abandoned
- 2003-01-23 EP EP03715324A patent/EP1471904A1/en not_active Withdrawn
- 2003-01-23 KR KR10-2004-7009147A patent/KR20040083471A/ko not_active Ceased
- 2003-02-05 AR ARP030100356A patent/AR038350A1/es unknown
- 2003-02-07 US US10/359,560 patent/US20040009926A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1471904A1 (en) | 2004-11-03 |
| CA2469925A1 (en) | 2003-08-14 |
| US20040009926A1 (en) | 2004-01-15 |
| AR038350A1 (es) | 2005-01-12 |
| PL374082A1 (en) | 2005-09-19 |
| KR20040083471A (ko) | 2004-10-02 |
| WO2003066041A1 (en) | 2003-08-14 |
| JP2005523269A (ja) | 2005-08-04 |
| AU2003219511A1 (en) | 2003-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kato et al. | Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder | |
| Renshaw et al. | Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study | |
| US8575219B2 (en) | Compounds for the treatment of psychiatric or substance abuse disorders | |
| Stanley et al. | Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study | |
| Moore et al. | Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? | |
| Willemsen et al. | Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome | |
| Puri et al. | Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes | |
| Silveri et al. | Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy | |
| US20100041621A1 (en) | Methods and compositions for improving cognitive performance | |
| Robertson et al. | Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. | |
| ES2245037T3 (es) | Utiizacion de compuestos que contienen citidina y que contienen citosina para el tratamiento de la exposicion a estimulantes. | |
| JP2007508315A (ja) | ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法 | |
| Moore et al. | Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study | |
| MXPA04007506A (es) | Carnitina en tratamiento de depresion geriartrica. | |
| Frederick et al. | Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline | |
| Smith et al. | Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease | |
| Graham et al. | Magnetic resonance spectroscopy of N‐acetylaspartate in hypoxic–ischemic encephalopathy | |
| US20100041620A1 (en) | Methods for improving frontal brain bioenergetic metabolism | |
| AL-SAMSAM et al. | Extracellular N-acetyl-aspartate as a biochemical marker of the severity of neuronal damage following experimental acute traumatic brain injury | |
| US20090215714A1 (en) | Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder | |
| US8013016B2 (en) | Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome | |
| Farber et al. | Choline metabolism, membrane phospholipids, and Alzheimer’s disease | |
| Scott | Childhood status epilepticus: structural consequences and assessment of a novel treatment | |
| Hiippil et al. | Quantitative lH-MRS in early human brain development and metabolic changes after perinatal brain injury | |
| Becker et al. | Safety and target engagement profile of two oxaloacetate doses in Alzheimer’s patients |